Ray, G.L.; Baidoo, K.E.; Keller, L.M.M.; Albert, P.S.; Brechbiel, M.W.; Milenic, D.E.
Pre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease. Pharmaceuticals 2012, 5, 1-15.
https://doi.org/10.3390/ph5010001
AMA Style
Ray GL, Baidoo KE, Keller LMM, Albert PS, Brechbiel MW, Milenic DE.
Pre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease. Pharmaceuticals. 2012; 5(1):1-15.
https://doi.org/10.3390/ph5010001
Chicago/Turabian Style
Ray, Geoffrey L., Kwamena E. Baidoo, Lanea M. M. Keller, Paul S. Albert, Martin W. Brechbiel, and Diane E. Milenic.
2012. "Pre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease" Pharmaceuticals 5, no. 1: 1-15.
https://doi.org/10.3390/ph5010001
APA Style
Ray, G. L., Baidoo, K. E., Keller, L. M. M., Albert, P. S., Brechbiel, M. W., & Milenic, D. E.
(2012). Pre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease. Pharmaceuticals, 5(1), 1-15.
https://doi.org/10.3390/ph5010001